These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 826968

  • 1. Haloperidol-induced tardive dyskinesia in monkeys.
    Gunne LM, Bárány S.
    Psychopharmacology (Berl); 1976 Nov 24; 50(3):237-40. PubMed ID: 826968
    [Abstract] [Full Text] [Related]

  • 2. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
    Domino EF.
    Psychopharmacology Suppl; 1985 Nov 24; 2():217-23. PubMed ID: 2860660
    [Abstract] [Full Text] [Related]

  • 3. Development of acute dystonia and tardive dyskinesia in cebus monkeys.
    Bárány S, Ingvast A, Gunne LM.
    Res Commun Chem Pathol Pharmacol; 1979 Aug 24; 25(2):269-79. PubMed ID: 115074
    [Abstract] [Full Text] [Related]

  • 4. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
    Psychopharmacology (Berl); 1986 Aug 24; 90(4):423-9. PubMed ID: 2880362
    [Abstract] [Full Text] [Related]

  • 5. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia.
    Gunne LM, Bárány S.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):195-8. PubMed ID: 39307
    [Abstract] [Full Text] [Related]

  • 6. Experimental tardive dyskinesia.
    Bédard PJ, Boucher R, Larochelle L.
    Prog Neuropsychopharmacol Biol Psychiatry; 1982 Jun 21; 6(4-6):551-4. PubMed ID: 6891821
    [Abstract] [Full Text] [Related]

  • 7. Application of a primate model for tardive dyskinesia.
    Bárány S, Häggström JE, Gunne LM.
    Acta Pharmacol Toxicol (Copenh); 1983 Feb 21; 52(2):86-9. PubMed ID: 6846025
    [Abstract] [Full Text] [Related]

  • 8. Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
    Fowler SC, Wang G.
    Psychopharmacology (Berl); 1998 May 21; 137(1):50-60. PubMed ID: 9631956
    [Abstract] [Full Text] [Related]

  • 9. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.
    Gunne LM, Häggström JE, Sjöquist B.
    Nature; 1998 May 21; 309(5966):347-9. PubMed ID: 6727989
    [Abstract] [Full Text] [Related]

  • 10. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
    Gerlach J, Simmelsgaard H.
    Psychopharmacology (Berl); 1978 Oct 31; 59(2):105-12. PubMed ID: 103110
    [No Abstract] [Full Text] [Related]

  • 11. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
    Shireen E, Naeem S, Inam QU, Haleem DJ.
    Pak J Pharm Sci; 2013 Mar 31; 26(2):271-6. PubMed ID: 23455196
    [Abstract] [Full Text] [Related]

  • 12. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH.
    Am J Psychiatry; 1997 Sep 31; 154(9):1248-54. PubMed ID: 9286184
    [Abstract] [Full Text] [Related]

  • 13. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
    Gerlach J, Casey DE.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Sep 31; 14(1):103-12. PubMed ID: 1967845
    [Abstract] [Full Text] [Related]

  • 14. Experimental tardive dyskinesia.
    Gunne LM, Häggström JE.
    J Clin Psychiatry; 1985 Apr 31; 46(4 Pt 2):48-50. PubMed ID: 2858481
    [Abstract] [Full Text] [Related]

  • 15. Dyskinesias evoked in monkeys by weekly administration of haloperidol.
    Weiss B, Santelli S.
    Science; 1978 May 19; 200(4343):799-801. PubMed ID: 417399
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological modification of experimental tardive dyskinesia.
    Bárány S, Gunne LM.
    Acta Pharmacol Toxicol (Copenh); 1979 Aug 19; 45(2):107-11. PubMed ID: 115227
    [Abstract] [Full Text] [Related]

  • 17. Clozapine in tardive dyskinesia: observations from human and animal model studies.
    Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM.
    J Clin Psychiatry; 1994 Sep 19; 55 Suppl B():102-6. PubMed ID: 7961550
    [Abstract] [Full Text] [Related]

  • 18. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A, Naidu PS, Kulkarni SK.
    Eur J Pharmacol; 2003 Sep 12; 477(2):87-94. PubMed ID: 14519411
    [Abstract] [Full Text] [Related]

  • 19. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L, Gerlach J.
    Eur J Pharmacol; 1993 Jun 24; 237(2-3):329-40. PubMed ID: 8103465
    [Abstract] [Full Text] [Related]

  • 20. Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias.
    Häggström JE, Gunne LM, Carlsson A, Wikström H.
    J Neural Transm; 1983 Jun 24; 58(3-4):135-42. PubMed ID: 6663299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.